Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBO-trial fractional subcutaneous mpox booster with MVA-BN
2024-510697-24-00Phase 3Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of JYNNEOS in mpox (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Geometric mean concentrations of VACV-specific antibodies. Planned start Dec 2024; status: authorised.
02
Drugs
JYNNEOS
03
Conditions
mpox
Beyond the preview
Go deeper on 2024-510697-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510697-24-00.